Morgan Stanley Lyra Therapeutics, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 652,381 shares of LYRA stock, worth $117,428. This represents 0.0% of its overall portfolio holdings.

Number of Shares

652,381

Previous 811,745 19.63%

Holding current value

$117,428

Previous $227,000 25.55%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.24 - $0.34 $38,247 - $54,183	-159,364 Reduced 19.63%	652,381 $169,000
Q2 2024 Oct 17, 2024	BUY	$0.26 - $6.25 $194,311 - $4.67 Million	747,353 Added 1160.63%	811,745 $227,000
Q2 2024 Aug 14, 2024	BUY	$0.26 - $6.25 $194,311 - $4.67 Million	747,353 Added 1160.63%	811,745 $227,000
Q1 2024 Oct 17, 2024	SELL	$4.55 - $6.53 $3.4 Million - $4.88 Million	-747,353 Reduced 92.07%	64,392 $400,000
Q1 2024 Aug 16, 2024	SELL	$4.55 - $6.53 $3.4 Million - $4.88 Million	-747,353 Reduced 92.07%	64,392 $400,000
Q1 2024 May 15, 2024	BUY	$4.55 - $6.53 $292,983 - $420,479	64,392 New	64,392 $400,000
Q2 2023 Aug 14, 2023	BUY	$1.98 - $4.33 $1,009 - $2,208	510 New	510 $2,000
Q4 2022 Feb 14, 2023	BUY	$2.44 - $5.42 $2 - $5	1 New	1 $0
Q2 2022 Aug 15, 2022	SELL	$4.12 - $7.51 $33,310 - $60,718	-8,085 Closed	0 $0
Q1 2022 Oct 27, 2022	BUY	$3.5 - $5.36 $28,297 - $43,335	8,085 New	8,085 $33,000
Q1 2022 May 13, 2022	SELL	$3.5 - $5.36 $4,711 - $7,214	-1,346 Reduced 14.27%	8,085 $33,000
Q4 2021 Feb 14, 2022	SELL	$4.22 - $9.41 $87,489 - $195,088	-20,732 Reduced 68.73%	9,431 $41,000
Q3 2021 Nov 15, 2021	BUY	$6.06 - $9.43 $182,787 - $284,437	30,163 New	30,163 $275,000

Others Institutions Holding LYRA

# of Institutions

Shares Held

32.2M

Call Options Held

21.1K

Put Options Held

400

View Full List

About Lyra Therapeutics, Inc.

Ticker LYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,826,400
Market Cap $5.73M
Description
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...

More about LYRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account